TY - JOUR
T1 - Enhanced Uptake and Retention of 0.03% Bimatoprost, 0.5% 5-Fluorouracil, and 5% Minoxidil After 1,550-nm or 1,927-nm Nonablative Laser Pretreatment
AU - Wang, Jordan V.
AU - Friedman, Paul M.
AU - Agron, Samantha
AU - Konda, Adarsh
AU - Parker, Catherine
AU - Geronemus, Roy G.
N1 - Funding Information:
Supported by Solta Medical (a division of Bausch Health US, LLC). Editorial assistance was provided under the direction of the authors by Carolyn H. Farnsworth, ELS, of MedThink SciCom, and funded by Solta Medical. Vikramaditya P. Bedi, a former employee of Solta Medical, was involved in the design and conduct of the study.
Publisher Copyright:
© 2022 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - BACKGROUND Laser pretreatment with cosmeceutical topicals is growing in popularity. However, lasers may also enhance the uptake of medical topicals that treat dermatologic conditions, such as vitiligo, alopecia, and cancerous and precancerous lesions. Permeation of these topicals must be quantified to optimize treatment protocols. OBJECTIVE To analyze transdermal uptake of 3 topicals after nonablative fractional 1,550-nm erbium-doped glass or 1,927-nm thulium fiber laser pretreatment. METHODS AND MATERIALS Human donor tissue was pretreated with a nonablative fractional 1,550-nm erbium-doped glass or 1,927-nm thulium fiber laser followed by application of 0.03% bimatoprost, 0.5% 5-fluorouracil, or 5% minoxidil. Permeation and retention were measured over 24 hours (bimatoprost and 5-fluorouracil) or 90 minutes (minoxidil), and uptake was calculated. RESULTS Pretreatment with 1,927-nm thulium laser (500 MTZ/cm2; 5 mJ; 5 W) enhanced uptake and retention of bimatoprost versus untreated control at 24 hours post-treatment. Pretreatment with 1,550-nm erbium-doped glass laser (2,000 MTZ/cm2; 10 mJ; 30 W) enhanced permeation, uptake, and retention of 5-fluorouracil at 24 hours post-treatment and enhanced permeation and uptake of minoxidil at 90 minutes post-treatment.CONCLUSION Nonablative laser pretreatment may enhance topical treatment of dermatologic conditions. Device settings must be optimized to maximize topical permeation while minimizing laser-associated thermal side effects.
AB - BACKGROUND Laser pretreatment with cosmeceutical topicals is growing in popularity. However, lasers may also enhance the uptake of medical topicals that treat dermatologic conditions, such as vitiligo, alopecia, and cancerous and precancerous lesions. Permeation of these topicals must be quantified to optimize treatment protocols. OBJECTIVE To analyze transdermal uptake of 3 topicals after nonablative fractional 1,550-nm erbium-doped glass or 1,927-nm thulium fiber laser pretreatment. METHODS AND MATERIALS Human donor tissue was pretreated with a nonablative fractional 1,550-nm erbium-doped glass or 1,927-nm thulium fiber laser followed by application of 0.03% bimatoprost, 0.5% 5-fluorouracil, or 5% minoxidil. Permeation and retention were measured over 24 hours (bimatoprost and 5-fluorouracil) or 90 minutes (minoxidil), and uptake was calculated. RESULTS Pretreatment with 1,927-nm thulium laser (500 MTZ/cm2; 5 mJ; 5 W) enhanced uptake and retention of bimatoprost versus untreated control at 24 hours post-treatment. Pretreatment with 1,550-nm erbium-doped glass laser (2,000 MTZ/cm2; 10 mJ; 30 W) enhanced permeation, uptake, and retention of 5-fluorouracil at 24 hours post-treatment and enhanced permeation and uptake of minoxidil at 90 minutes post-treatment.CONCLUSION Nonablative laser pretreatment may enhance topical treatment of dermatologic conditions. Device settings must be optimized to maximize topical permeation while minimizing laser-associated thermal side effects.
UR - http://www.scopus.com/inward/record.url?scp=85137159405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137159405&partnerID=8YFLogxK
U2 - 10.1097/DSS.0000000000003532
DO - 10.1097/DSS.0000000000003532
M3 - Article
C2 - 36054045
AN - SCOPUS:85137159405
VL - 48
SP - 932
EP - 936
JO - Dermatologic Surgery
JF - Dermatologic Surgery
SN - 1076-0512
IS - 9
ER -